Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy

Journal of the American Society of Nephrology

Volumn 7, Issue 2, 1996, Pages 290-298

  Ambalavanan, Siva ^a   Fauvel, Jean Pierre ^a   Sibley, Richard K ^a   Myers, Bryan D ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibition; Barrier function; Filtration dynamics; Glomerular morphometry

Indexed keywords

ANGIOTENSIN; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENALAPRIL; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 0029974552     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Zietse R, Wenting GJ, Kramer P: Contrasting response to cyclosporine in refractory nephrotic syndrome. Clin Nephrol 1989;31:22-28.
2. DeSanto NG, Capodicasa G, Giordano C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporine. Am J Nephrol 1989;7:74-76.
3. Rostoker G, Ben Maadi A, Sandreux: Cyclosporine in idiopathic steroid resistant membranous glomerulonephritis. Lancet 1989;2:975-976.
4. Cattran DC: Current status of cyclosporin A in the treatment of membranous,IgA and membroproliferative gomerulonephritis. Clin Nephrol 1991;35:43-47.
5. Guasch A, Suranyi M, Newton L, Hall BM, Myers BD: Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am J Kidney Dis 1992;20:472-481.
6. Rostoker G, Belghiti D, Maadi AB, et al.: Long term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993;63:335-341.
7. Cameron SJ, Healy JR, Adu D: The medical research council trial of short term high dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 1990;274:133-156.
8. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term prednisolone treatment in adults with membranous nephropathy. N Engl J Med 1979;301:1301-1306.
9. Imperiale TF, Goldfarb S, Berns JS: Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol 1995;5:1553-1558.
10. Couser WG: Mediation of immune glomerular injury. J Am Soc Nephrol 1990;1:13-29.
11. Couser WG, Abrass CK: Pathogenesis of membranous nephropathy. Annu Rev Med 1988;39:17-30.
12. Borel JF: Pharmacology of cyclosporine (Sandimmune). IV. Pharmacological properties in vivo. Pharmacol Rev 1989;41:259-371.
13. Remuzzi G, Schieppati A, Garattini S: Treatment of idiopathic membranous glomerulopathy. Current opinion in nephrol and hypertension. 1994;3:155-163.
14. Myers BD, Newton L: Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991;2:S45-S52.
15. Ting RH, Kristol B, Myers BD: The biophysical basis of hypofiltration in nephrotic humans with membranous nephropathy. Kidney Int 1994;45:390-397.
16. Guasch A, Sibley RK, Huie P, Myers BD: Extent and course of glomerular injury in human membranous glomerulopathy. Am J Physiol (Renal Fluid Electrolyte Physiol) 1992;32:F1034-F1043.
17. Canaan-Kuhl S, Venkatraman ES, Ernst SIB, Olshen RA, Myers BD: Relationships among protein and albumin concentrations and oncotic pressure in nephrotic plasma. Am J Physiol (Renal Fluid and Electrolyte Physiol) 1993;33:F1052-F1059.
18. Battilana C, Zhang H, Olshen R, Wexler L, Myers BD: PAH extration and the estimation of plasma flow in the diseased human kidney. Am J Physiol 1991;30:F726-F733.
19. Deen WM, Bridges CR, Brenner BM, Myers BD: A heteroporous model of size selectivity : application to normal and nephrotic humans. Am J Physiol 1985;249: F374-F389.
20. Myers BD, Gausch T: Selectivity of the glomerular filtration barrier in healthy and nephrotic humans. Am J Nephrol 1993;13:311-317.
21. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
22. Myers BD, Sibley R, Newton L, et al.: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988;33:590-660.
23. Myers BD, Newton L, Boshkos C, et al.: Chronic injury of human renal microvessels with "low-dose" cyclosporine therapy. Transplantation 1988;46:694-703.
24. Drumond MC, Kristal B, Myers BD, Deen WM: Structural basis for reduced glomerular filtration capacity in nephrotic humans. J Clin Invest 1994;94:1187-1195.
25. Falk RJ, Hogan SL, Muller KE, et al.: Treatment of progressive membranous glomerulopathy. Ann Intern Med 1992;116:438-445.
26. Reichert LJM, Huysmans FM, Assmann K, Koene RAP, Wetzels JFM: Preserving renal function in patients with membranous nephropathy: Daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994;121:328-333.
27. Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisolone. Ann Intern Med 1991;114:725-730.
28. Zietse R, Winting GJ, Kramer P, Schalekamp MA, Weimar W: Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci 1992;82: 641-650.
29. Gausch A, Deen WM, Myers BD: Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J Clin Invest 1993;92:2274-2282.
30. Guasch A, Hashimoto H, Sibley RK, Deen WM, Myers BD: Glomerular dysfunction in nephrotic humans with minimal changes or focal glomerulosclerosis. Am J Physiol (Renal Fluid and Electrolyte Physiol) 1991;29: F728-F737.
31. Rostoker G, Maadi AB, Remy P, Lang P, Lagrue G, Weil B: Low dose angiotensin converting enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: A prospective study of long-term treatment. Nephrol Dial Transplant 1995;10:25-29.
32. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope L, Rodicio JL: Long-term beneficial effects of Angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-248.
33. Thomas DM, Hillis AN, Cikes GA, Davies M, Williams JD: Enalapril can treat the proteinuria of membranous glomerulonephritis without detriment to systemic or renal hemodynamics. Am J Kidney Dis 1991;18:38-43.
34. Gansevoort RT, Heeg JE, Vriesendorp R, Zeeuw D, Jong PE: Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol Dial Transplant 1992;1:91-96.
35. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993;118:129-138.
36. Morelli E, Loon N, Meyer T, Peters W, Myers BD: Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76-82.
37. Heymann W, Hunter JLP, Hackel DB: Experimental autoimmune nephrosis in rats. J Immunol 1962;88: 135-142.
38. Alexopoulos E, Seron D, Hartley B, et al.: Immune mechanisms in idiopathic membranous nephropathy: The role of the interstitial infiltrates. Am J Kidney Dis 1989;13:404-412.
39. Quiza CG, Leenaerts PL, Hall BM: The role of T cells in the mediation of glomerular injury in Heymann's nephritis in the rat. Int Immunol 1992;4:423-432.
40. Gronhagin-Riska C, Von Willebrand E, Tikkanen T, et al.: The effect of cyclosporin A on the interstitial mononuclear cell infiltration and the induction of Heymann's nephritis. Clin Exp Immunol 1990;79:266-272.
41. Cattran DC: Effect of cyclosporin on active Heymann nephritis. Nephron 1988;48:142-148.
42. Cattran DC, Greenwood C, Lavoie S, et al.: A controlled trial of cyclosporin in patients with progressive membranous nephropathy. Kidney Int 1995;47:1130-1135.